Clinical trials
Anemia trials in Israel
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
43 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 6 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 24 |
| Unknown status | 7 |
| Active, not recruiting | 4 |
| Terminated | 4 |
| Recruiting | 3 |
| No longer available | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Akebia Therapeutics | 3 |
| Amgen | 3 |
| Bayer | 3 |
| Celgene | 3 |
| HaEmek Medical Center, Israel | 3 |
| Novartis Pharmaceuticals | 2 |
| OrSense, Ltd. | 2 |
| Soroka University Medical Center | 2 |
| Takeda | 2 |
| Aevi Genomic Medicine, LLC, a Cerecor company | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Anemia | 43 |
| Renal Insufficiency, Chronic | 9 |
| Myelodysplastic Syndromes | 8 |
| Iron Deficiencies | 4 |
| Primary Myelofibrosis | 4 |
| Anemia, Iron-Deficiency | 3 |
| Renal Insufficiency | 3 |
| Bone Marrow Diseases | 2 |
| Hematologic Diseases | 2 |
| Myeloproliferative Disorders | 2 |
Trials
Showing 26 to 43 of 43. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.